|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||13.25 - 13.25|
|52-week range||13.25 - 13.25|
|Beta (5Y monthly)||1.27|
|PE ratio (TTM)||21.65|
|Forward dividend & yield||0.11 (0.81%)|
|Ex-dividend date||18 Mar 2021|
|1y target est||N/A|
BURLINGAME, Calif., October 08, 2021--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today it has entered into an arrangement with Clinigen Group plc ("Clinigen") a global pharmaceutical Services and Products company, to implement a Managed Access Program for lenzilumab ("LenzMAP™").
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Clinigen Group plc...